While CELMoDs frequently cause neutropenia, this effect is most pronounced in early cycles and manageable with growth factors. This contrasts sharply with the persistent, quality-of-life-impairing non-hematologic side effects of lenalidomide, such as rash and severe fatigue. This trade-off results in a significantly better long-term tolerability profile for patients.

Hedgehog inhibitors for basal cell carcinoma cause significant side effects like dysgeusia and muscle cramps. To improve tolerability and long-term adherence, clinicians use practical strategies like scheduled treatment interruptions (e.g., weeks on, weeks off) rather than continuous daily dosing.

When managing side effects from highly effective therapies like MEK inhibitors, it's often better to temporarily hold treatment and then resume at the original dose rather than immediately dose-reducing. This strategy maintains dose intensity, which is critical for maximizing the drug's therapeutic benefit.

To manage Dasatinib's common side effect of pleural effusions, a randomized study showed that skipping doses on weekends is superior to dose reduction. This strategy leverages the drug's short half-life, maintaining peak levels for efficacy while providing a break from off-target effects that cause toxicity.

Data from the DREAM 7 trial reveals that holding belantamab doses for 12 weeks or longer to manage ocular toxicity did not negatively impact progression-free survival (PFS). Responding patients often maintain their response, challenging the conventional wisdom that strict dosing schedules are paramount for efficacy.

To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.

To combat the significant myelosuppression from the standard 28-day venetoclax cycle in AML, many clinicians are adopting a strategy of performing a bone marrow biopsy around day 21 and pausing the drug if blast clearance is achieved to allow for hematologic recovery.

To manage infection risk and improve quality of life, experts are quickly reducing bispecific antibody dosing frequency (e.g., to monthly) once a response is achieved. This real-world practice deviates from rigid trial schedules to optimize patient outcomes.

The ERA SAFE study found that a bi-weekly, lower-dose docetaxel regimen for triplet therapy significantly lowers grade 3-4 adverse events compared to the standard 3-week schedule. It reduced the risk of neutropenic fever from 5.5% to 1.7% while maintaining similar efficacy, offering a safer alternative for frail or vulnerable patients.